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Abstract 28 
While the role for the individual Notch receptors in early hematopoiesis have been thoroughly 29 
investigated in mouse, studies in human have been mostly limited to the use of pan-Notch 30 
inhibitors. However, such studies in human are important to predict potential side-effects of 31 
specific Notch receptor blocking reagents since these are currently being considered as 32 
therapeutic tools to treat various Notch-dependent diseases. Here, we studied the individual 33 
roles of Notch1 and Notch3 in early human hematopoietic lineage decisions, particularly 34 
during T-lineage specification. While this process in mice is solely dependent on Notch1 35 
activation, we recently reported Notch3 expression in human uncommitted thymocytes, 36 
raising the possibility that Notch3 mediates human T-lineage specification. Although 37 
expression of a constitutive activated form of Notch3 (ICN3) results in the induction of T-38 
lineage specification in human CD34
+
 hematopoietic progenitor cells, similar to ICN1 39 
overexpression, loss-of-function studies using blocking antibodies reveal that only Notch1, 40 
but not Notch3, is critical in this process. Blocking of Notch1 activation in OP9-DLL4 co-41 
cultures resulted in a complete block in T-lineage specification and induced monocytic and 42 
plasmacytoid dendritic cell differentiation instead. In fetal thymus organ cultures, impeded 43 
Notch1 activation resulted in B and dendritic cell development. In contrast, Notch3 blocking 44 
antibodies only marginally affected T-lineage specification and hematopoietic differentiation 45 
with a slight increase in monocyte development. No induction of B or dendritic cell 46 
development was observed. Thus, our results unambiguously reveal a non-redundant role for 47 
Notch1 in human T-lineage specification, despite the expression of other Notch receptors.  48 
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Introduction 49 
In mammals, the Notch pathway is composed of a highly conserved family of four different 50 
Notch receptors (Notch1-4) that can be activated through five different ligands (Delta like 1, 3 51 
and 4 and Jagged 1 and 2). Activation results in cleavage of the transmembrane Notch 52 
receptor, thereby releasing the intracellular part of the protein (intracellular Notch, ICN) that 53 
subsequently migrates to the nucleus to activate downstream Notch target gene expression (1). 54 
Notch signaling is involved in various developmental programs and cell fate decisions (2). As 55 
a result, Notch mutations have been implicated in various malignancies, including 56 
neurological disorders (3), cancers (4) and immune-related diseases. A well-known example 57 
includes aberrant Notch1 activation that is involved in over 60% of T-acute lymphoblastic 58 
leukemia cases (5), while activating Notch3 mutations have been implicated in various tumors 59 
(6,7). Due to the broad activity of Notch signaling, the therapeutic potential of pan-Notch 60 
blocking reagents, such as gamma-secretase inhibitors, has been hampered as a result of 61 
significant side-effects which may be overcome with Notch receptor specific reagents such as 62 
monoclonal antibodies (8,9).  63 
Unfortunately, limited information is available on the effects that Notch receptor specific 64 
blocking reagents might have on human hematopoiesis. However, such knowledge is crucial 65 
because of the involvement of Notch signaling in the development of various normal and 66 
malignant blood cell types (10-14). While specific gene deletion studies in mice have revealed 67 
critical roles for Notch1 and Notch2, Notch3 seems less critical during hematopoietic 68 
differentiation in the mouse. Since species differences exist, studies in human are of critical 69 
translational importance. Indeed, previous work from our lab and others, although mostly 70 
limited to pan-Notch activation and inhibition experiments, confirmed certain roles for Notch 71 
activation in early hematopoietic lineage decisions (15-18), but also revealed some subtle 72 
differences during intrathymic stages of T cell development (16,19-22). In more recent work, 73 
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we revealed a critical role for Jagged2-mediated Notch3 activation in human TCR-γδ T cell 74 
development (23), a mechanism that seems absent in mouse (24,25). In that study, we also 75 
observed that CD34
+
CD1a
-
 human thymocytes, immature uncommitted T-lineage progenitors 76 
in the human postnatal thymus, express significant NOTCH3 mRNA levels, in addition to 77 
NOTCH1 mRNA. While it is clear in the mouse that Notch1 (26) is the only receptor that is 78 
involved in the specification of multipotent hematopoietic progenitor cells into the T cell 79 
pathway as a result of activation through Delta-like-4 (27,28), it is still unclear which Notch 80 
receptors mediate this process in human. The question is particularly relevant since Jagged2, a 81 
strong Notch3 ligand, is abundantly expressed by cortical thymic epithelial cells (18), the 82 
region inside the thymus where the first Notch signals are provided to early thymic 83 
progenitors (29). While DLL4 is also expressed within that region, it is inefficient at binding 84 
and activating Notch3 (23,25). 85 
Given our recent findings that Notch3 is expressed early during human T cell development 86 
and that this receptor modulates human T-cell lineage decisions (23), we investigated in this 87 
study the requirement of both Notch1 and Notch3 in the early stage of human T cell 88 
specification by specific overexpression or inhibition of one of these Notch receptors. Our 89 
results show that Notch3 is able to induce T cell lineage specification in the absence of 90 
Notch1 activation, but that Notch3 is not essential in this process. Thus, in accordance with 91 
observations in the mouse model, Notch1 is the only Notch receptor that is essential to induce 92 
early T-lineage specification. 93 
94 
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Materials and methods 95 
Cell samples 96 
 97 
Cord blood units that did not meet the criteria for banking were obtained from the 98 
Navelstrengbloedbank UZ Gent and thymus tissue was obtained from children undergoing 99 
cardiac surgery (UZ Gent). Both were obtained and used according to the guidelines of the 100 
Medical Ethical Commission of Ghent University Hospital (Ghent, Belgium).  101 
Mononuclear cells were collected after centrifugation over Lymphoprep and were, if 102 
necessary, cryopreserved in 10% dimethylsulfoxide, 90% fetal calf serum until required.  103 
Cord blood cells or thymocytes were enriched for CD34
+
 cells using magnetic microbeads 104 
(Miltenyi Biotec), according to the manufacturer’s instructions. Cord blood cells were then 105 
stained with CD34-APC (Miltenyi), CD3-FITC, CD14-FITC, CD19-FITC, CD56-FITC (BD 106 
Biosciences) and sorted for CD34
+
lin
−
 using a FACSAriaII cell sorter (BD Biosciences). 107 
Purity of the sorted cells was always >95%. Purity of thymocytes following CD34
+
 magnetic 108 
purification was always >98%. 109 
Generation of plasmids and viruses. 110 
 111 
cDNA encoding constitutively active Notch3 was subcloned from previously described 112 
constructs (30) into the multicloning site of the retroviral vector MSCV-EGFP. Generation of 113 
the plasmid containing ICN1 has been described previously (16). Retroviral transduction of 114 
cord blood has been described (31). ICN1 and ICN3 protein expression levels following 115 
transduction of human progenitor cells was validated previously (23). 116 
OP9 cocultures and Fetal thymus organ cultures. 117 
 118 
Retrovirally transduced progenitors were first sorted for EGFP
+
 cells and subsequently seeded 119 
onto plates (24-well or 96-well) containing a confluent layer of OP9-control or OP9-DLL4 120 
cells. OP9 cocultures were all performed in -MEM media (Invitrogen) supplemented with 121 
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20% heat-inactivated FCS (Hyclone) plus 100 U/ml penicillin, 100 µg/ml streptomycin and 122 
2mM L-glutamin (all from Invitrogen) (18,32). CD34
+
Lin
-
 cells were cultured in the presence 123 
of 5 ng/ml IL-7, 5 ng/ml Flt-3L and 5 ng/ml SCF. In blocking experiments, 5 µg/ml isotype 124 
control, anti-Notch1 (9) or anti-Notch3 antibody (8) was added to the medium and half of the 125 
medium was refreshed every 3-4 days to keep the antibody concentration stable. 126 
Fetal thymus organ cultures (FTOCs) were performed as described previously (33) NOD-127 
LtSz-scid/scid (NOD-SCID) mice, originally purchased from The Jackson Laboratory (Bar 128 
Harbor, ME), were obtained from our own specific pathogen-free breeding facility. NOD-129 
SCID mice were treated according the guidelines of the Laboratory Animal Ethical 130 
commission of the University Hospital of Ghent. Fetal thymic lobes from these mice were 131 
isolated at fetal day 15-15.5 of gestation. 2000-10000 human cord blood cells were added to 132 
each lobe in medium containing 20 µg/ml G3 isotype control, anti-Notch1 (9)  or anti-Notch3 133 
antibody (8). After 2 days in hanging drop, lobes were transferred to FTOC in medium 134 
containing 15 µg/ml G3 isotype control, anti-Notch1 or anti-Notch3 antibody. Half of the 135 
medium was refreshed every 3-4 days. 136 
Lymphocytes from cultures were counted using a hematocytometer and human cellularity was 137 
quantified following determination of the frequency of human CD45
+
 cells (and EGFP in case 138 
of transduced cells) by flow cytometry.   139 
Monoclonal antibodies and flowcytometry 140 
 141 
Cell suspensions obtained from cocultures were first blocked with anti-mouse FcRII/III 142 
(clone 2.4.G2) and human IgG (Fcblock, Miltenyi) to avoid non-specific binding. Cell 143 
suspensions obtained after FTOCs were also blocked with anti-mouse FcRII/III  mAb and 144 
stained with rat anti-mouse monoclonal antibody CD45-cychrome to gate out mouse cells 145 
during flowcytometry. Subsequently, cells were stained with combinations of anti-human 146 
monoclonal antibodies as indicated and previously described (18). Cells were examined for 147 
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the expression of cell surface markers on a LSRII (BDIS) and human viable cells were gated 148 
by excluding propidium iodide positive cells from analysis. 149 
Quantitative RT-PCR 150 
 151 
Two days after transduction with ICN1, ICN3 or control, cells were sorted for eGFP 152 
expression, were resuspended in RLT-buffer and stored at -70°C prior to RNA isolation. RNA 153 
was extracted using RNeasy RNA isolation kit (Qiagen) and converted into cDNA using 154 
Superscript RT II (Invitrogen).  155 
Real-time PCR reactions were performed using qPCR Core kit for SYBR
®
 Green I 156 
(Eurogentec) on a 7300 Real-time PCR system (Applied Biosystems Relative expression 157 
levels were calculated for each gene using the Ct method using -actin for normalization. 158 
Statistical analysis 159 
 160 
Statistical significance was calculated using the non-parametric paired Wilcoxon test from 161 
SPSS version 22.0 software. 162 
163 
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Results 164 
Notch3 is expressed in the majority of human early thymocyte progenitors (ETPs). 165 
While the precise identity of the human equivalent of mouse ETPs is still a matter of debate 166 
(34-37), it is clear that the most immature human thymocytes reside within the CD34
+
CD1a
-
 167 
population. We have previously shown that bulk CD34
+
CD1a
-
 thymocytes express both 168 
NOTCH1 and NOTCH3 mRNA (23), but now extend these results by investigating protein 169 
expression for Notch3 at the single cell level using flow cytometry. As illustrated in Figure 1, 170 
over 90% of these cells display Notch3 protein expression at the cell surface. While this 171 
frequency further increases in T cell committed CD34
+
CD1a
+
 thymocytes (Figure 1), these 172 
findings indicate that Notch3 activation can occur very early during human T cell 173 
development and thus may influence the T-lineage specification process.  174 
 175 
Notch3 overexpression can support early T cell development in vitro. 176 
The high frequency of Notch3 expressing cells within the most immature human thymocytes 177 
urged us to investigate whether Notch3 has a role in the induction of human T-lineage 178 
specification. We first determined if Notch3 has the potential to induce human T cell 179 
development in the absence of other Notch receptor stimuli. Therefore, human CD34
+
lin
-
 180 
hematopoietic progenitor cells from cord blood were transduced (Figure 2A) with an EGFP 181 
control virus, or with viruses encoding EGFP in addition to the intracellular activated forms of 182 
Notch1 or Notch3 (ICN1 or ICN3, respectively), and, following sorting to start with a nearly 183 
100% transduced and homogeneous population (Figure 2B), cultured on OP9-control or OP9-184 
DLL4 stromal cells in cytokine conditions that promote T cell differentiation.  185 
As expected, EGFP control transduced progenitor cells did not differentiate into CD34
+
CD7
+
 186 
(Figure 2C, 2D) and CD7
+
CD5
+
 T-lineage specified cells (Figure 2G, 2H) on OP9-control 187 
stromal cells, in contrast to on OP9-DLL4 cells. Consistent with previous results, ICN1 was 188 
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sufficient to induce T cell development in human precursors, and this was also the case when 189 
ICN3 was continuously expressed, indicating that Notch3 activation could be sufficient in the 190 
absence of Notch1 activation to induce human T lineage specification (Figure 2C, 2D, 2G, 191 
2H). Levels of transduction remained consistent throughout the coculture (Figure 2E, 2F). 192 
Interestingly, ICN3 was more efficient at inducing T-lineage specification compared to ICN1 193 
when cocultured on OP9-DLL4 (although not statistically significant, Figure 2D, 2H), 194 
suggesting a synergistic effect of Notch1 (activated through DLL4) and Notch3 activation on 195 
early T cell development, similar as documented previously in T-lineage committed human 196 
thymocytes (23) but in contrast to earlier reports that suggested a negative feedback of Notch3 197 
signaling on Notch1 activity (38).   198 
Consistently, gene expression analysis revealed that the direct Notch target genes HES1, 199 
DTX1, NRARP and IL7R were upregulated  48 hours after transduction with both ICN1 and 200 
ICN3 (Figure 3) and in agreement with earlier work (23), ICN3 was a stronger inducer of the 201 
most sensitive Notch target genes (DTX1 and NRARP) (22) compared to ICN1. Interestingly, 202 
while ICN1 has the potential the induce NOTCH3 expression, the reverse seems not possible 203 
as ICN3 transduced cells display virtually no upregulation of NOTCH1 expression (Figure 3). 204 
In agreement with the capacity of ICN1 and ICN3 transduced cells to differentiate along the 205 
T-cell lineage, myeloid genes such as CSFR1 (encoding MCSFR) and SPI1 (encoding PU.1) 206 
were downregulated by both Notch receptors. 207 
In conclusion, these results show that Notch3 activation is sufficient to induce T-lineage 208 
specification in human multipotent hematopoietic progenitor cells. 209 
 210 
Notch3, but not Notch1, is dispensable for induction of human T-lineage specification. 211 
Experiments in human have thus far revealed that Notch signaling is essential to induce T-212 
lineage specification, but it is still unclear which Notch receptor is driving this process. While 213 
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the above experiments reveal that both Notch1 and Notch3 are expressed in the most 214 
immature thymocyte subsets and that both can induce T-lineage specification, they did not 215 
reveal their requirements in this process. Therefore, we used Notch1 and Notch3 specific 216 
blocking antibodies at concentrations known to fully block receptor activation (8,9) to reveal 217 
which Notch receptors are critical in this process. Their specificity was confirmed using 218 
quantitative RT-PCR for Notch target genes in CD34
+
 thymocytes exposed to either DLL4 or 219 
JAG2 in OP9 cocultures. Consistent with the fact that DLL4 is a good Notch1 but a poor 220 
Notch3 ligand, blocking of Notch1 completely abolished Notch target gene expression in 221 
OP9-DLL4 cocultured cells, while blocking Notch3 antibodies had very little effect (Figure 222 
4A). In contrast, Jagged2 can activate both Notch1 and Notch3, and consistently, blocking 223 
Notch3 antibodies now also efficiently blocked Notch target gene expression, although 224 
residual Notch activity was observed as a result of remaining Notch1 activation. Notch1 225 
blocking antibodies also fully blocked Notch3 activity in OP9-JAG2 cocultures since Notch3 226 
is a downstream Notch1 target during early T cell development in mouse and human (22,39).  227 
In the presence of a Notch1 blocking antibody, CD34
+
lin
-
 hematopoietic progenitors from CB 228 
fail to differentiate into CD34
+
CD7
+
 and CD7
+
CD5
+
 T-lineage precursors on OP9-DLL4 229 
stromal cells, in contrast to when a control antibody is added (Figure 4B, 4C). In the presence 230 
of a Notch3 blocking antibody, CD34
+
CD7
+
 and CD7
+
CD5
+
 thymocytes can develop (Figure 231 
4B) with only a small, but significant, reduction in the number of CD7
+
CD5
+
 cells (Figure 232 
4C).  233 
Notch-induced T-lineage specification is accompanied by inhibition of myeloid differentiation 234 
and consistently, blocking of Notch1 activation resulted in a significant increase in the 235 
development of conventional CD4
+
HLA-DR
+
 dendritic cells, CD11b
+
CD14
+
 monocytes and 236 
CD123
+
CD303
+
 plasmacytoid dendritic cells (Figure 5A, 5B). Inhibition of Notch3 activation 237 
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resulted in a small increase in the development of conventional dendritic cells and monocytes, 238 
but no difference in plasmacytoid dendritic cell differentiation was observed (Figure 5A, 5B). 239 
To test the requirement for Notch1 and Notch3 in a more physiological setting, we added 240 
these inhibiting monoclonal antibodies in an FTOC since DLL4 is not the only Notch ligand 241 
that is expressed within the thymus (18,21,40,41). Consistent with our findings in OP9-DLL4 242 
cocultures, however, Notch1 inhibition resulted in a block in CD7
+
CD5
+
 T-lineage 243 
specification and an overall reduction in cell numbers, while Notch3 inhibition did not 244 
significantly influence this process (Figure 6A, 6B). In agreement, myeloid differentiation as 245 
well as CD19
+
HLA-DR
+
 B-lineage development was only increased compared to the control 246 
when Notch1 signaling was inhibited, not upon Notch3 inhibition (Figure 6A, 6B). Overall, 247 
these results show that T-lineage specification in human is dependent on Notch1 activation, 248 
not Notch3. 249 
250 
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Discussion 251 
We have previously illustrated that human uncommitted CD34
+
CD1a
-
 thymocytes not only 252 
express Notch1, but also Notch3 (23). Here, we further analyzed Notch3 protein surface 253 
expression within the most immature population of human postnatal thymocytes and reveal 254 
that the majority of these cells already express Notch3 protein. Given that we have previously 255 
revealed important differences in Notch signaling activity between mouse and human (20-256 
23,42-44), this prompted us to investigate whether Notch3 activation was critical at the 257 
earliest stages of human T cell development, during T-lineage specification. While activation 258 
of Notch1 or Notch3 by itself was sufficient to induce T cell development in human 259 
multipotent hematopoietic progenitors, specific blocking monoclonal antibodies revealed that 260 
only Notch1, not Notch3, is critical to drive this process and to inhibit alternative lineage 261 
differentiation. Thus, our results show that Notch1 activation is the first driver of T cell 262 
development in both mouse and human. 263 
The ability of ICN3 to induce T-lineage commitment in the absence of Notch1 activation is in 264 
line with recent findings in mice that show that ICN1, ICN2, ICN3 and ICN4 all can induce T 265 
cell development when overexpressed in murine hematopoietic progenitor cells (45). While 266 
the intracellular regions of Notch1 and Notch2 possess a transactivation domain between the 267 
ANK and PEST sequences, Notch3 lacks a conventional version of this domain (46). 268 
Nevertheless, the precise role of this transactivation domain is still unclear and earlier work 269 
has suggested that this domain is weaker at activating downstream target gene expression in 270 
case of Notch3 compared to the conventional TAD in Notch1, and that it even can inhibit 271 
Notch1-mediated transactivation (38). Based on their capacity to induce T-lineage 272 
specification on OP9-GFP stromal cells in the absence of Notch ligands, our findings suggest 273 
that ICN3 on its own is indeed a weaker Notch activator compared to ICN1 since this process 274 
is strongly dependent on Notch signal strength (22). While this may seem in contrast with the 275 
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gene expression profiles in which ICN3 induces stronger activation of the most sensitive 276 
Notch target genes DTX1 and NRARP, both these targets are considered to be negative 277 
regulators of Notch activity (47,48), leaving it unclear whether Notch3 truly is weaker at 278 
activating downstream target genes, a phenomenon that may also be cell type specific (46). 279 
However, in conjunction with Notch1 activation on OP9-DLL4, ICN3 synergizes with ICN1 280 
to induce a stronger Notch activation signal as observed through a more efficient induction of 281 
T-lineage specification compared to ICN1 by itself. Given that ICN dimerization can critically 282 
influence downstream target gene expression (49), further studies that can specifically study 283 
ICN1 homodimers and ICN1-ICN3 heterodimers could be very informative. 284 
Previous work from our lab has shown that a large subset of human cortical thymic epithelial 285 
cells express the Notch ligand Jagged2 (18) and that this ligand preferentially binds and 286 
activates Notch3 (23). Although cortical epithelial cells are responsible for inducing T cell 287 
development in immigrating precursors and despite the fact that the majority of immature 288 
CD34
+
CD1a
-
 thymocytes express Notch3, the results from this manuscript suggest that the 289 
Jagged2/Notch3 interaction is not critical during T-lineage specification. Although these 290 
findings are in line with data from other species, such as unambiguous data obtained from 291 
genetic mouse models (24-26), the fact that Notch3 is expressed at such a high level at these 292 
earliest stages of human T cell development, combined with the abundant expression of 293 
Jagged2 on cTECs, suggests however a prominent role for this receptor/ligand interaction 294 
during early T cell development in human. While we were unable to reveal a role in the T-295 
lineage specification process, one caveat may involve the technical approaches that we used 296 
since foetal thymus colonization occurs differently compared to postnatal (50) and thus some 297 
caution is required in the interpretation of our FTOC results. Nevertheless, the gene 298 
expression analysis that was performed to validate the specificity of the blocking monoclonal 299 
antibodies indicates that Notch3 function is highly dependent on Notch1 activity during the 300 
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earliest stages of human T cell development, but not vice versa. While this can be explained 301 
by the observation that Notch3 is a downstream target of Notch1 in both mouse (39) and 302 
human(22), it further confirms that Notch1 triggering is the first critical Notch signaling event 303 
that is required to induce T-lineage specification. Since extrathymic progenitor cells express 304 
Notch1 and Notch2, but not Notch3, the induction of Notch3 upon Notch1 activation seems to 305 
reflect ETPs that have received initial Notch1 signaling events. We now show that, besides 306 
Notch1 activation, triggering of the additional expressed Notch3 receptor that is induced 307 
through Notch1 activation is not required to complete the T-lineage specification process. 308 
Given that DLL4 is a stronger Notch1 activator compared to JAG2 (18), that this ligand is 309 
also expressed by human cTECs (18) and that T-lineage specification is dependent on strong 310 
Notch activation (22), it seems likely that the DLL4/Notch1 interaction, similar as in the 311 
mouse (26-28), is the major Notch signaling event that induces T cell development in 312 
immigrating thymic progenitors. As also illustrated in this manuscript, this specification event 313 
coincides with the repression of B and myeloid cell development, lineage potentials that are 314 
lost during the T-cell specification process that occurs immediately upon thymic entry of 315 
multipotent progenitor cells and of which we now reveal that they are Notch3 independent. 316 
Further studies will be required to investigate whether Notch3 activation is involved in 317 
inducing T-lineage commitment, a process that follows T cell specification and that is 318 
characterized by the loss of NK cell potential. In each case, Notch1-induced upregulation of 319 
Notch3 following thymus colonization of thymic progenitors does play a critical role later 320 
during human T cell development as we have recently illustrated that the Jagged2/Notch3 321 
interaction mediates human TCR-γδ T cell development (23).  322 
Together, while our findings confirm previous work from mice, the results from this 323 
manuscript are the first experiments in human to unambiguously reveal that Notch1 is the 324 
driving force to initiate T cell development from multipotent hematopoietic precursors since 325 
  15 
virtually all previous human studies on hematopoiesis used pan Notch inhibitors, including 326 
gamma-secretase inhibitors or the dominant-negative mastermind-like 1 protein. To reveal the 327 
specific requirement for Notch1 in the initial stages of human T cell development was 328 
important, not only from a fundamental perspective because of the abundant Notch3 329 
expression early during T cell development, but also from a clinical perspective since Notch3 330 
blocking antibodies may have significant therapeutic potential in patients that display Notch3 331 
driven tumors (6,7). Our findings indicate that administration of Notch3 blocking antibodies 332 
should have limited impact on early hematopoietic lineage decisions since Notch3 function 333 
seems limited to synergizing with Notch1, thereby limiting potential side effects.  334 
335 
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Figure legends 526 
Figure 1 527 
Notch3 is expressed by the majority of human early thymocyte progenitors. 528 
(A) Gating strategy for CD34
+
 human postnatal thymocytes following CD34 MACS 529 
enrichment. (B) Flow cytometric analysis of cell surface Notch3 expression on CD34
+
CD1a
-
 530 
uncommitted and CD34
+
CD1a
+
 committed thymocyte populations as indicated. Data shown is 531 
representative for at least 4 independent stainings on 4 different thymus donors. 532 
 533 
Figure 2 534 
Notch3 activation induces T cell development. 535 
(A) Control, ICN1 or ICN3 transduced CD34
+
Lin
-
 cord blood progenitors were (B) sorted for 536 
EGFP expression and (C-H) subsequently cultured on OP9 stromal cells that express the 537 
Notch ligand Delta-like-4 or control OP9 cells that express no Notch ligand, as indicated. Dot 538 
plots in (C) and (G) are gated on human CD45
+
EGFP
+
 cells. Numbers in the quadrants 539 
indicate the percentage of cells for the corresponding populations after 6 (C) or 10 (G) days of 540 
coculture. (E) and (F) show, within human CD45
+
 gated cells, the frequency of EGFP positive 541 
cells following 10 days of coculture on OP9-control or OP9-DLL4, respectively. Dot plots 542 
shown are representative for 5 independent experiments. (D) and (H) show the absolute cell 543 
numbers for the corresponding populations in panels C (day 6) and G (day 10), respectively. 544 
Graphs show the average of 5 independent experiments, error bars indicate SEM (* p<0.05).  545 
 546 
Figure 3 547 
Notch1 and Notch3 activation induces Notch target gene expression. 548 
  23 
Quantitative RT-PCR analysis of Notch target genes and genes that are critical for driving non 549 
T-cell lineages in human CD34
+ 
cord blood cells, sorted for EGFP expression 2 days after 550 
transduction with ICN1, ICN3, or control virus. The expression levels are normalized to -551 
actin levels. Data shown are the mean of 5 sets of independent samples and error bars show 552 
SEM (* p<0.05). 553 
 554 
Figure 4 555 
Notch3, but not Notch1, is dispensable for induction of human T-lineage specification. 556 
(A) Notch target gene expression analysis in CD34
+
 thymocytes following 48 hours of 557 
coculture on OP9-DLL4 or OP9-JAG2 stromal cells in the presence of control, Notch1 or 558 
Notch3 blocking antibodies. mRNA levels are normalized to -actin levels and shown relative 559 
to the control antibody for each culture condition. Data are the mean of two sets of 560 
independent samples and error bars show SEM. (B) Flow cytometric analysis of CD34
+
Lin
-
 561 
cord blood progenitors after 12 days of coculture on OP9 stromal cells that express the Notch 562 
ligand Delta-like-4 and in the presence of control or blocking anti-Notch1 or anti-Notch3 563 
antibody. Dot plots are gated on human CD45
+
 cells and numbers in quadrants indicate the 564 
percentage of cells for the corresponding populations. Dot plots shown are representative for 565 
6 independent experiments. (C) Absolute cell numbers for the corresponding populations in 566 
(B), as indicated. Graphs show the average of 6 independent experiments, error bars indicate 567 
SEM (* p<0.05). 568 
 569 
Figure 5 570 
Notch1 inhibition induces myeloid lineage differentiation. 571 
(A) Flow cytometric analysis of myeloid differentiation from CD34
+
Lin
-
 cord blood 572 
progenitors after 2 weeks of coculture on OP9-DLL4 stromal cells in the presence of control 573 
  24 
or blocking anti-Notch1 or anti-Notch3 antibody. Dot plots are gated on human CD45
+
 cells 574 
and numbers in the dot plots indicate the percentage of cells for the corresponding 575 
populations. Dot plots shown are representative for 6 independent experiments. (B) Absolute 576 
cell numbers for the corresponding populations from (A), as indicated. Graphs display the 577 
average of 6 independent experiments, error bars indicate SEM (* p<0.05).  578 
 579 
Figure 6 580 
Intrathymic Notch1 inhibition induces alternative lineage differentiation. 581 
CD34
+
Lin
-
 cord blood progenitors were submitted to FTOC, in the presence of control, anti-582 
Notch1 or anti-Notch3 blocking antibody. (A) Dot plots are gated on human lymphocytes and 583 
numbers in dot plots indicate the percentage of cells for the corresponding populations after 2 584 
weeks of FTOC. Dot plots shown are representative for 7 independent experiments. (B) 585 
Absolute cell numbers for the corresponding populations from (A), as indicated. Graphs show 586 
the average of 7 independent experiments, error bars indicate SEM (* p<0.05). 587 
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